Avid Bioservices to Highlight Recent Successes in Reducing Manufacturing Costs and Novel Ways of Controlling Critical Process

Avid Bioservices to Highlight Recent Successes in Reducing Manufacturing Costs 
and Novel Ways of Controlling Critical Process
Parameters That Lead to Consistent Product Quality at IBC'S
Biopharmaceutical Development and Production Conference 
Solutions to Increase Lifetime of Purifications Resins to Decrease
Production Costs; Successful Utilization of a Quality by Design (QbD)
Approach to Identify Critical Process Parameters That Control
Critical Quality Attributes (CQAs) 
TUSTIN, CA and HUNTINGTON BEACH, CA -- (Marketwire) -- 02/26/13 -- 
Avid Bioservices, Inc., a subsidiary of Peregrine Pharmaceuticals,
Inc. (NASDAQ: PPHM), today announced that it will present two posters
at IBC's Biopharmaceutical Development & Production Conference to be
held in Huntington Beach, California, February 26 - March 1, 2013.
Avid will highlight its expertise in optimizing purification and
scale-up processes in order to reduce overall cost of goods for
manufactured products and its use of Quality by Design (QbD)
experiments to identify important process parameters critical to
maintaining a consistent quality product profile. All of the studies
were performed at its cGMP manufacturing facility in Orange County,
California, to support Avid's manufacturing projects. 
"Quality by Design is an important concept in the development of
biologics and we have applied these strategies in keeping with
industry best standards, to identify critical process parameters
(CPPs) and to make continuous production improvements, that reliably
produce a high quality product for our clients," said Jeff Masten,
vice president of quality for Avid Bioservices. "The concepts and
methodology we are using at Avid are the same systems we successfully
used at Genentech to achieve high success rates and consistent
product quality. We are pleased to be able to integrate this approach
into our processes."  
The following posters from Avid Bioservices will be on display in the
exhibit hall February 27th & 28th, 2013 at the Hyatt Regency
Huntington Beach Resort and Spa Hotel: 
"Extending Ceramic Hydroxyapatite (CHT) Column Life at Manufacturing
Scale through Small-Scale Optimization" 
"Quality by Design Approach Results in the Discovery of a Process
Parameter that Increases Afucosylation" 
In addition, Avid Bioservices will have representatives at Booth #320
in the main hall.  
"Our teams are constantly pursuing new ways to optimize processes and
methods to meet the changing needs of advancing programs," said
Connie Chang, director of process science for Avid Bioservices. "In
both studies being presented, we were able to make significant
improvements in manufacturing processes, which resulted in
efficiencies that will significantly lower the cost of goods and
allow us to better control the quality of the product. Our ongoing
QbD projects will evaluate the effect of CPPs on CQAs, as we continue
to further optimize and control processes moving toward Phase III
clinical trials and commercialization."  
For additional information on IBC's Antibody Development and
Production Conference, please visit
http://www.ibclifesciences.com/BDPWeek/overview.xml 
About Avid Bioservices
 Avid Bioservices provides a comprehensive
range of high quality cGMP manufacturing services for the
biotechnology and biopharmaceutical industries to support the
manufacture of cGMP clinical phase and commercial products. With over
10 years of experience producing monoclonal antibodies and
recombinant proteins in batch, fed-batch and perfusion modes, Avid's
services include GMP clinical and commercial product manufacturing,
purification, bulk packaging, final product filling, stability
testing and regulatory strategy, submission and support. The company
also provides a variety of process development activities, including
cell line optimization, cell culture and feed optimization,
analytical methods development and product characterization. For more
information about Avid, please visit www.avidbio.com. 
About Peregrine Pharmaceuticals
 Peregrine Pharmaceuticals, Inc. is a
biopharmaceutical company with a portfolio of innovative monoclonal
antibodies in clinical trials for the treatment of cancer and serious
viral infections. The company is pursuing multiple clinical programs
in cancer and infectious diseases with its lead product candidate
bavituximab and novel brain cancer agent Cotara(R). Peregrine also
has in-house cGMP manufacturing capabilities through its wholly-owned
subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides
development and biomanufacturing services for both Peregrine and
outside customers. Additional information about Peregrine can be
found at www.peregrineinc.com.  
Safe Harbor Statement: Statements in this press release which are not
purely historical, including statements regarding Avid Bioservices'
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. The forward-looking statements involve risks and
uncertainties including, but not limited to, the risk that Avid's
revenue growth may slow or decline, the risk that Avid may experience
technical difficulties in processing customer orders which could
delay delivery of products to customers and receipt of payment, and
the risk that one or more existing Avid customers, including those
with committed manufacturing or representing its backlog, terminates
its contract prior to completion. It is important to note that the
Avid's actual results could differ materially from those in any such
forward-looking statements. Avid's business could be affected by a
number of factors, including the risk factors listed from time to
time in the Peregrine Pharmaceuticals, Inc.'s SEC reports including,
but not limited to, its annual report on Form 10-K for the fiscal
year ended April 30, 2012 and quarterly report on Form 10-Q for the
quarter ended October 31, 2012. Avid cautions investors not to place
undue reliance on the forward-looking statements contained in this
press release. Avid disclaims any obligation, and does not undertake
to update or revise any forward-looking statements in this press
release. 
Contact:
Chris Keenan
Kelly Pisarev Lord
(800) 987-8256
www.avidbio.com 
 
 
Press spacebar to pause and continue. Press esc to stop.